Key result
A 62-year-old female breast cancer patient developed severe mitral regurgitation after anthracycline exposure, with symptoms significantly relieved by heart failure medical therapy.
Case Report (n=1)
No
Incipient mitral regurgitation may serve as an early sign of anthracycline-induced cardiotoxicity, and prompt initiation of heart failure medical therapy can relieve symptoms and delay the need for surgical correction.
Answers are grounded in this paper and cite their sources.
Case suggests anthracycline-induced mitral regurgitation may respond to medical therapy; hypothesis-generating and should not yet change practice.
RATIONALE: Anthracyclines cardiotoxicity characterized by dilated myocardiopathy has been well described in the literature. However, anthracyclines-induced valvular diseases have been seldom reported. PATIENT CONCERNS: In this study, we present the case of a 62-year-old Chinese female patient with breast cancer developing severe mitral regurgitation after anthracycline exposure. DIAGNOSES: The patient was diagnosed with mitral regurgitation with preserved left ventricular ejection fraction and normal cardiac chamber dimensions in the sixth month after the last course of anthracycline-containing chemotherapy. However, continued decrease in LVEF with normal left ventricular wall thickness, and serial increases in left atrial and ventricular dimensions were observed in the follow-up echocardiography. INTERVENTIONS: Treatments with oral itraconazole at a dose of 75 mg/day and local wound care with ciclopirox olamine ointment were administered. OUTCOMES: The patient responded well to the treatment with perindopril, metoprolol succinate, spirolactone, and furosemide, and symptoms associated with heart failure were dramatically relieved. LESSONS: The incipient mitral regurgitation may serve as an early sign of myocardial dysfunction that can facilitate a timely recognition of cardiotoxicity, which is crucial to a timely change of chemotherapy regimen and an appropriate initiation of antiremodeling therapy that could limit anthracycline cardiotoxicity and improve overall outcome.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) conducted a case report in Mitral regurgitation after anthracycline-based chemotherapy (n=1). Heart failure medical therapy (perindopril, metoprolol, spirolactone, furosemide) was evaluated on Clinical response and echocardiographic changes. A 62-year-old female breast cancer patient developed severe mitral regurgitation after anthracycline exposure, with symptoms significantly relieved by heart failure medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: